Search research articles
Contact Us
Filters
Showing results (161-170 of 178) with videos related to
Page
of 18
Sort By:
The Biochemical Journal
|
July 21, 2023
SUFU promotes GLI activity in a Hedgehog-independent manner in pancreatic cancer
Brooke D Paradise, Vladimir G Gainullin, Luciana L Almada, et al.
Molecular and Cellular Biology
|
May 23, 2026
A Novel Emerin/Nesprin-3 Interaction Mediates Nuclear Size Changes Induced by Oncogenic KRAS in Pancreatic Cancer Cells
Kayla C LaRue-Nolan, Luis F Flores, Renzo E Vera, et al.
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms
|
February 26, 2023
GLI1, a novel target of the ER stress regulator p97/VCP, promotes ATF6f-mediated activation of XBP1
Luciana L Almada, Kim Barroso, Sandhya Sen, et al.
Immunopharmacology and Immunotoxicology
|
March 9, 2010
Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma
Moisés A Franco-Molina, Edgar Mendoza-Gamboa, Pablo Zapata-Benavides, et al.
The Journal of Biological Chemistry
|
May 31, 2025
Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2-collagen I signaling
Renzo E Vera, Maite G Fernandez-Barrena, Jose M Falero, et al.
Beneficial Microbes
|
February 19, 2020
Intravaginal administration of gelatine capsules containing freeze-dried autochthonous lactobacilli: a double-blind, randomised clinical trial of safety
P R De Gregorio, N C Maldonado, E Vera Pingitore, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 2, 2025
Nuclear Galectin-1 promotes <i>KRAS</i>-dependent activation of pancreatic cancer stellate cells
Judith Vinaixa, Neus Martínez-Bosch, Joan Gibert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
The Journal of Biological Chemistry
|
May 28, 2026
KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53
Ezequiel J Tolosa, Glancis L Raja Arul, Ashley N Sigafoos, et al.
JCI Insight
|
June 10, 2025
Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer
Luis F Flores, David L Marks, Renzo E Vera, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 178) with videos related to
Sort By:
Page
of 18
The Biochemical Journal
|
July 21, 2023
SUFU promotes GLI activity in a Hedgehog-independent manner in pancreatic cancer
Brooke D Paradise, Vladimir G Gainullin, Luciana L Almada, et al.
Molecular and Cellular Biology
|
May 23, 2026
A Novel Emerin/Nesprin-3 Interaction Mediates Nuclear Size Changes Induced by Oncogenic KRAS in Pancreatic Cancer Cells
Kayla C LaRue-Nolan, Luis F Flores, Renzo E Vera, et al.
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms
|
February 26, 2023
GLI1, a novel target of the ER stress regulator p97/VCP, promotes ATF6f-mediated activation of XBP1
Luciana L Almada, Kim Barroso, Sandhya Sen, et al.
Immunopharmacology and Immunotoxicology
|
March 9, 2010
Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma
Moisés A Franco-Molina, Edgar Mendoza-Gamboa, Pablo Zapata-Benavides, et al.
The Journal of Biological Chemistry
|
May 31, 2025
Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2-collagen I signaling
Renzo E Vera, Maite G Fernandez-Barrena, Jose M Falero, et al.
Beneficial Microbes
|
February 19, 2020
Intravaginal administration of gelatine capsules containing freeze-dried autochthonous lactobacilli: a double-blind, randomised clinical trial of safety
P R De Gregorio, N C Maldonado, E Vera Pingitore, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 2, 2025
Nuclear Galectin-1 promotes <i>KRAS</i>-dependent activation of pancreatic cancer stellate cells
Judith Vinaixa, Neus Martínez-Bosch, Joan Gibert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
The Journal of Biological Chemistry
|
May 28, 2026
KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53
Ezequiel J Tolosa, Glancis L Raja Arul, Ashley N Sigafoos, et al.
JCI Insight
|
June 10, 2025
Emerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer
Luis F Flores, David L Marks, Renzo E Vera, et al.
Page
of 18